Leerink Partners analyst Mani Foroohar reiterated a Buy rating on Intellia Therapeutics (NASDAQ:NTLA) on Friday, setting a price target of $81, which is approximately 14.67% above the present share price of $70.64.
Foroohar expects Intellia Therapeutics to post earnings per share (EPS) of -$0.69 for the second quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Intellia Therapeutics, with an average price target of $81.4.
The analysts price targets range from a high of $106 to a low of $60.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $6.6 million and a net profit of -$42.4 million. The company's market cap is $5.42 billion.
According to TipRanks.com, Leerink Partners analyst Mani Foroohar is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 0.4% and a 47.46% success rate.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.